### How Informative were Early SARS-CoV-2 Treatment and Prevention Trials? A longitudinal cohort analysis of trials registered on clinicaltrials.gov

Nora Hutchinson<sup>1</sup> M.D., C.M., MPhil

Katarzyna Klas<sup>2</sup>

Benjamin G. Carlisle<sup>3</sup> PhD

Jonathan Kimmelman<sup>1</sup> PhD

Marcin Waligora<sup>2\*</sup> PhD

1. Studies of Translation, Ethics, and Medicine (STREAM), Biomedical Ethics Unit,

McGill University, Montreal, Québec, Canada

2. Research Ethics in Medicine Study Group (REMEDY), Faculty of Health Sciences,

Jagiellonian University Medical College, Krakow, Poland

3. Berlin Institute of Health at Charité (BIH), BIH QUEST Center for Transforming Biomedical Research, Berlin, Germany

\* Correspondence: Marcin Waligora (m.waligora@uj.edu.pl)

## Abstract

#### Background

Early in the SARS-CoV-2 pandemic, commentators warned that some COVID trials were inadequately conceived, designed and reported. Here, we retrospectively assess the prevalence of informative COVID trials launched in the first 6 months of the pandemic.

#### Methods

We created a cohort of SARS-CoV-2 treatment and prevention efficacy trials that were initiated from 2020-01-01 to 2020-06-30 using ClinicalTrials.gov registration records. We evaluated trials on 3 criteria of informativeness: potential redundancy, design quality and feasibility of patient-participant recruitment. The study protocol was prospectively registered with the Open Science Framework (https://osf.io/fp726/).

#### Results

We included 500 trials in our cohort, 58% of which were Phase 2 and 84.8% were directed towards the treatment of SARS-CoV-2. Close to one third of trials met all three criteria and were deemed informative (29.0% (95% Confidence Interval 23.7 – 36.9)). The proportion of potentially redundant trials in our cohort was 4.1%. Over half of the trials in our cohort (56.2%) did not meet our criteria for high quality trial design. The proportion of trials with infeasible patient-participant recruitment was 22.6%.

#### Conclusions

Less than one third of COVID-19 trials registered on ClinicalTrials.gov during the first six months met all three criteria for informativeness. Shortcomings in trial design,

recruitment feasibility and redundancy reflect longstanding weaknesses in the clinical research enterprise that were likely amplified by the exceptional circumstances of a

pandemic.

### Keywords

SARS-CoV-2, COVID-19, clinical trials, informativeness, redundancy, trial design,

recruitment, ethics

## Introduction

Starting in early 2020, commentators warned of COVID-19 clinical trial design deficiencies and lack of coordination of research efforts.<sup>1-4</sup> The large volume of small trials investigating the efficacy of repurposed medications, such as hydroxychloroquine, in the treatment of COVID-19, drew particular attention.<sup>5,6</sup> Such studies confounded an effective public health response by producing spurious findings, or by diverting patients and resources from well designed and executed studies.

Appropriate design, implementation and reporting is captured by the concept of trial "informativeness".<sup>3,7</sup> For a trial to be informative, it must ask a clinically important question, be designed to provide a clear answer, be feasible, be analyzed in a manner that supports statistically valid inference, and report results in a complete and timely manner.<sup>3,7</sup>

In the following longitudinal cohort analysis of SARS-CoV-2 treatment and prevention trials registered within the first 6 months of 2020, we assess three features of an informative clinical trial - potential redundancy, design quality and feasibility of patient-participant recruitment. Multiple cross-sectional analyses and systematic reviews of SARS-CoV-2 treatment and prevention trials have been performed,<sup>2,5,6,8-10</sup> reporting on intervention types, study characteristics and choice of outcome measure. We go beyond a description of trial characteristics and provide the first in-depth evaluation of SARS-CoV-2 trial informativeness. Knowing the prevalence of potentially uninformative trials

conducted in the early stages of the pandemic can help motivate the development of more effective research policy in anticipation of future public health crises.

# Methods

### Sample, design and trials selection

Our cohort consisted of interventional SARS-CoV-2 treatment and prevention trials registered on ClinicalTrials.gov with a start date between 2020-01-01 and 2020-06-30. We included Phase 1/2, Phase 2, Phase 2/3 and Phase 3 trials testing an efficacy hypothesis in their primary outcome. We included trials evaluating any of the following interventions: drug, biological, surgical, radiotherapy, procedural or device (see S1 File for complete inclusion/exclusion criteria). Trial inclusion was independently assessed by two researchers (KK & LZ). We did not perform a sample size calculation, as we included all trials meeting our eligibility criteria within our designated sampling timeframe.

### **Data curation**

We downloaded clinical trial data directly as a zipped folder of XML files from the web front-end of ClinicalTrials.gov on 2020-12-01 and again on 2021-01-04. This allowed us to evaluate data at the 6-month mark (from date of trial start) for all trials in our cohort (see S2 File for data directly downloaded from ClinicalTrials.gov). Additional items

requiring human curation were independently assessed and coded by two researchers (KK & LZ), these included: i) treatment type (according to the World Health Organization (WHO) COVID-19 Classification of treatment types<sup>11</sup>); ii) illness severity (as stated by the study investigators or guided by the WHO disease severity classification<sup>12</sup>); iii) location of care (ambulatory, hospitalized, intensive care, unclear/not stated); iv) presence of a placebo or standard of care arm; and, v) type of primary outcome (clinical, surrogate, procedural) (see S3 File for additional double-coded data points).

### Measures

Trials were assessed based on three elements of informativeness articulated elsewhere:<sup>3,7</sup> i) potential redundancy (as a marker of trial importance); ii) trial design quality; and iii) successful patient-participant recruitment (as a marker of feasibility). Assessment criteria for each element were designed based on face validity and easy applicability over a large trial sample.

#### **Potential redundancy**

We assessed potential redundancy by evaluating non-redundancy of the trial hypothesis. Non-redundancy was defined as: absence of a trial of the same phase, type of trial (SARS-CoV-2 prevention versus treatment), patient-participant characteristics (including location of care, disease severity and age of trial participants), regimen (including interventions used in combination in a single arm), comparator arm(s) and primary outcome (evaluating primary outcome domain and specific measurement,

based on framework from<sup>13</sup>) launched prior to the start date of the trial of interest (as indicated in the registration record active at the 6-month mark since trial start) (S4 File). Only the trial with the later start date was labelled as potentially redundant. The assessment was independently performed by two raters (NH & KK). We performed an additional *post hoc* assessment applying a broad criterion for trial similarity, which we defined as presence of a trial with an earlier start date of the same type, phase, patient-participant characteristics and treatment regimen.

### **Design quality**

We analyzed trial design quality for those studies in our sample that were aimed at informing clinical practice – namely Phase 2/3 and Phase 3 trials. Based on the U.S. Food & Drug Association (FDA) May 2020 guidance document for SARS-CoV-2 drug and biological treatment and prevention trials,<sup>14</sup> we considered a trial to be well-designed if it was randomized, placebo-controlled (with appropriate standard of care in all arms), double-blinded and included participants aged 60 years or over (as a proxy for an at-risk population). To be considered well-designed, a trial must also measure an appropriate primary outcome – a clinical primary outcome in the case of trials aimed at treating COVID-19, or the presence of laboratory-confirmed SARS-CoV-2 infection for trials testing a preventive measure.

### **Feasibility of Patient-Participant Recruitment**

We assessed timeliness and success of patient-participant recruitment for each trial in our cohort. A single trial was considered non-feasible if it met any of the following criteria: i) trial status was "terminated" or "suspended" and reason for stopping contained a rationale unrelated to trial efficacy, safety or the progression of science; ii) trial status was "completed" or "active, not recruiting" and final enrollment was less than 85% of the anticipated enrollment reported in the trial registration at the time of trial launch (given concerns for compromised statistical power for the primary outcome when recruitment is below the stated threshold (based on previously published methods<sup>15</sup>); or, iii) trial status was "recruiting" or "enrolling by invitation" and the recruitment period had been extended to at least twice as long as the anticipated length in the version of ClinicalTrials.gov registration record at the time of trial start.

### **Data analysis**

We report the overall proportion of trials meeting all three criteria of informativeness (potential redundancy, design quality and feasibility of patient-participant recruitment) as well as the proportion meeting each of our three criteria. We performed a stratified analysis of the proportion of i) non-redundant; ii) well-designed; and iii) feasible trials by sponsor (industry versus non-industry), trial country location (USA versus non-USA), trial type (treatment versus prevention) and number of trial centers (single center versus multicenter). Ninety-five percent confidence intervals were calculated for each proportion and the Fisher's exact test was used to compare proportions within each group and calculate *p*-values. We defined p < 0.05 as statistically significant. All tests were 2-tailed.

### Tools and data synthesis

We performed data extraction using Numbat Systematic Review Manager v. 2.11 (<u>RRID:SCR\_019207</u>).<sup>16</sup> All analyses were performed using R version 3.6.3.<sup>17</sup> We retrieved historical versions of ClinicalTrials.gov using Clinical Trials History Scraper (RRID:SCR\_019229).

Our study was not subject to Institutional Review Board approval, as it relies on publicly accessible data and did not involve interaction with research participants. The study protocol was prospectively registered on Open Science Framework.<sup>18</sup> We listed the deviations from the protocol in S5 File. The code<sup>19</sup> and data sets<sup>18</sup> used in this analysis are available online.

### **Results**

We included 500 interventional SARS-CoV-2 treatment and prevention efficacy trials (see S1 Figure for PRISMA Diagram). The majority (58.0%) of trials in our cohort were Phase 2 trials; 84.6% were randomized; 84.8% were directed at the treatment of SARS-CoV-2. Study status at 6 months since trial start was "completed" in 54 of 500 trials (10.8%) and "Recruiting" in 67.0% (Table 1). Median anticipated enrollment per trial (based on the enrollment stated in the last registration record prior to trial start) was 180 patient-participants (interquartile range (IQR) 60-437). Median actual patient-participant

enrollment at the 6-month mark, for those trials that provided actual enrollment numbers, was 129 (IQR 32-320).

Less than one third (29.9%, 95% CI 23.7-36.9%) of the 194 trials eligible for assessment of all 3 criteria were deemed informative. Nineteen trials were classified as potentially redundant (4.1%), of which 10 investigated convalescent plasma and a further 4 investigated hydroxychloroquine. Sixty-three trials (13.6%) differed only by primary outcome. In our *post hoc* analysis, 81.9% (380 of 464 trials) were similar with respect to trial type, regimen, phase and patient-participant characteristics.

Of the subset of 210 Phase 2/3 and Phase 3 trials in our cohort, 92 (43.8%) met our criteria for trial design quality<sup>20</sup> (Figure 1; Table 2). The proportion of feasible trials in our cohort was 77.4% (387 of 500 trials); 113 trials were non-feasible. Of these, 12 were suspended or terminated for a reason unrelated to efficacy, safety or the progression of science; 20 trials were "active, not recruiting" or completed but failed to enrol at least 85% of their target patient-participant enrollment (S2 Figure); 81 trials still recruiting had exceeded at least two times the intended recruitment period (S3 Figure).

## Discussion

This is the first study to assess the prevalence of informative COVID-19 clinical trials. In our analysis, 29.9% of early COVID-19 trials registered on ClinicalTrials.gov met our 3 criteria for informativeness. Many (56.2%) did not use rigorous design, based on

assessment of randomization, control group, blinding, primary outcome, and inclusion of an at-risk population. Of these, the greatest number (110 of 210 trials, 52.4%) did not demonstrate adequate blinding. Lack of blinding among COVID-19 trials has been highlighted in several recent analyses<sup>2,5,6,9,10</sup> and may reflect the challenges of trial conduct in pandemic circumstances, in which significant research infrastructure and oversight is required to implement and maintain blinding. Yet, deficits in trial design were not uniform. Our stratified results (Table 3) demonstrated that trials with at least one center in the USA, in addition to trials with industry sponsorship, SARS-CoV-2 prevention trials and multicenter trials, demonstrated a greater proportion of welldesigned trials than their counterparts.

Despite elevated SARS-CoV-2 cases, many trials (22.6% (113 of 500 trials)) were unable to adequately and expeditiously complete patient-participant recruitment. This estimate is in keeping with other studies in which close to one third of COVID-19 trials registered on ClinicalTrials.gov or on the World Health Organization International Clinical Trials Registry Platform stopped before attaining 75% accrual.<sup>20</sup> In some cases failure to reach recruitment goals can be explained by decreasing case counts in the setting of rapid suppression of a COVID outbreak. For example, early stoppage of a Remdesivir multicenter randomized controlled trial after recruitment of 237 of 453 patient-participants in Wuhan, China, resulted in an underpowered trial with inconclusive results.<sup>21,22</sup> This has also been seen in other settings, such as in the 2014-2016 Ebola outbreak.<sup>23</sup> However, infeasible recruitment targets, despite high case counts, have also been documented during the COVID-19 pandemic.<sup>24</sup> Trial feasibility may be particularly challenging in the fractured US healthcare setting due to inter-trial competition in patient-participant recruitment, as supported by our stratified analysis in which non-USA trials were significantly more likely to be feasible than USA trials.

Lack of coordination and trial prioritization, resulting in a high level of multiplicity in investigated interventions, is a contributing factor to infeasible patient-participant recruitment. Concern about trial redundancy has been brought up frequently during the COVID-19 pandemic<sup>1,2,4,5</sup> In our study, only 4.1% of trial were deemed potentially redundant, of which 4 investigated hydroxychloroguine and 10 investigated the efficacy of convalescent plasma. Our categorization of trials as potentially redundant involved matching of trial phase, type of trial (treatment versus prevention), patient-participant characteristics, regimen, comparator and primary outcome. It differs from other assessments of SARS-CoV-2 trial duplication, in which trial intervention has been the main focus of assessment.<sup>2</sup> While a low proportion of potentially redundant trials may be seen as an encouraging result, deeper examination reveals that sixty-three trials (13.6%) assessed for potential redundancy differed only by the choice of primary outcome, with endpoints often demonstrating small deviations from comparator trials, of guestionable clinical relevance. For instance, some trials expressed the primary endpoint as a function of time e.g., time to death, whereas in others as a rate e.g., case fatality rate. Lack of research coordination and harmonization of primary outcome endpoints during the COVID-19 pandemic<sup>2,4,25,26</sup> can thwart efforts to clarify net effects

through meta-analyses. This is particularly relevant in the setting of multiple small trials of specific interventions, where the probability is elevated that at least one trial produces a positive result by chance alone.<sup>2,5</sup>

Concerns regarding research waste predated the pandemic<sup>27-33</sup> but intensified in the setting of this international public health crisis. Our results support arguments for devising coordinated research plans in advance of public health emergencies, and evaluating and prioritizing trials at institutional,<sup>34,35</sup> state and national levels.<sup>36</sup> The success of multicenter national platform trials, such as RECOVERY, in the United Kingdom, in both recruiting patient-participants (over 41000 have been enrolled as of August 9 2021, https://www.recoverytrial.net) and in generating practice-changing evidence, speaks to the promise of national research prioritization.<sup>37</sup> In our stratified analysis, industry-sponsored trials were significantly more likely to meet all 3 informativeness criteria than non-industry sponsored trials (Table 3). This suggests that academic researchers require more institutional support, as well as assistance from research consortia and funding bodies to produce informative results.

### Limitations

First, we limited our assessment to 3 aspects of trial informativeness – potential redundancy, design quality and feasibility of patient-participant recruitment. Other aspects of informativeness, such as integrity and reporting, were not evaluated in our study, as they cannot be assessed without access to final trial results (430 of 500 trials,

86.0% had not yet completed or terminated at the end of our 6-month follow-up period). Second, we used proxy measures of informativeness, which are imperfect. For example, we adopted strict criteria for potential redundancy, resulting in only 19 trials labelled potentially redundant, many of which differed based on primary outcome alone. Our *post hoc* analysis resulted in over eighty percent of trials deemed similar, based on assessment of trial type, regimen, phase and patient-participant characteristics. These two results (4.1% and 81.9%) can be viewed as lower and upper bounds for the proportion of redundant trials. Future research will be required to provide a more precise estimate post-pandemic. Our assessment of trial design quality, as guided by the May 2020 FDA guidance document,<sup>14</sup> required that all trials be, at a minimum, doubleblinded. We acknowledge that this may unfairly penalize the small minority of trials evaluating interventions in which double-blinding is not practicable. In addition, our assessment of the inclusion of at-risk populations was limited only to age. We did not assess whether the study included a population with other risk factors such as comorbidities. However, no trials failed our design criteria based on failure to include an at-risk population. Third, our assessment of the informativeness of COVID-19 trials depends on the accuracy of ClinicalTrials.gov registration records.

# Conclusions

The SARS-CoV-2 pandemic was met with a vigorous response from clinical researchers. However, less than one third of early COVID-19 trials registered on ClinicalTrials.gov met our 3 criteria for informativeness. Shortcomings in trial design,

recruitment feasibility and redundancy reflect longstanding vulnerabilities in the clinical research enterprise that were magnified by the urgency of a pandemic. Much knowledge has been gained during the past 18 months, both in terms of effective measures aimed at treatment and prevention of the virus, but also with respect to the conduct of informative clinical research. The task ahead will be for investigators, research institutions, sponsors and regulators alike to take stock of lessons learned and devise solutions to benefit the global research enterprise as we move forward.

# **Supporting information**

- S1 File. Trial Inclusion and Exclusion Criteria
- S2 File. Data downloaded from ClinicalTrials.gov
- S3 File. Additional data points
- S4 File. Assessment of Trial Redundancy
- S5 File. Protocol Deviations
- S1 Figure. PRISMA Diagram
- S2 Figure. Ratio of Actual to Estimated Number of Patients Enrolled
- S3 Figure. Ratio of Actual to Estimated Recruitment Length

## Acknowledgments

We thank Lucja Zabrowska for her important contribution to the data extraction for this project and Maciej Polak for statistical consultancy.

# Authors' contributions

Conceptualization: Nora Hutchinson, Katarzyna Klas, Benjamin Gregory Carlisle,

Marcin Waligora

Data curation: Katarzyna Klas

Formal analysis: Nora Hutchinson, Benjamin Gregory Carlisle

Funding Acquisition: Marcin Waligora

Investigation: Nora Hutchinson, Katarzyna Klas, Benjamin Gregory Carlisle

Methodology: Nora Hutchinson, Katarzyna Klas, Benjamin Gregory Carlisle, Jonathan

Kimmelman, Marcin Waligora

Project Administration: Nora Hutchinson, Marcin Waligora

Software: Nora Hutchinson, Benjamin Gregory Carlisle

Supervision: Marcin Waligora

Visualization: Nora Hutchinson

Writing of the original draft: Nora Hutchinson

Writing, review and editing: Nora Hutchinson, Katarzyna Klas, Benjamin Gregory

Carlisle, Jonathan Kimmelman, Marcin Waligora

The authors read and approved the final manuscript.

## Funding

This study was funded by the National Science Center, Poland, UMO 2020/01/0/HS1/00024 (<u>www.ncn.gov.pl</u>). Authors received the funding: MW, KK. The

funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

# Availability of data and materials

The datasets generated and analysed during the current study are available in the Open Science Framework repository, https://osf.io/fp726/.

# Ethics approval and consent to participate

Not applicable.

# **Competing interests**

Marcin Waligora reports personal fees from Advisory Bioethics Council, Sanofi outside

the submitted work. Other authors have declared that no competing interests exist.

Category	Number of	Percent	Median (IQR)	Median (IQR)
	Trials	Total	Anticipated	Actual
	(N = 500)	(%)	Enrollment <sup>a</sup>	Enrollment <sup>b</sup>
Trial Phase				
Phase 2 <sup>c</sup>	290	58.0	100 (40-200)	60 (25-152)
Phase 3 <sup>d</sup>	210	42.0	400 (183-1000)	241 (95-494)
Randomization				
Randomized	423	84.6	200 (82-482)	142 (53-357)
Non-Randomized	30	6.0	73 (30-248)	38 (20-102)
NA <sup>e</sup>	47	9.4	38 (20-100)	27 (10-50)
Trial Status <sup>f</sup>				
Completed	54	10.8	100 (46-396)	100 (40-387)
Terminated	16	3.2	265 (150-464)	62 (7-127)
Active, Not Recruiting	71	14.2	240 (68-500)	177 (55-442)
Recruiting	335	67.0	152 (60 – 410)	143 (26-230)
Enrolling by Invitation	11	2.2	128 (56-400)	72 (51-152)
Suspended	13	2.6	308 (200-600)	27 (5-71)
Trial Type				
Treatment Trial	424	84.8	130 (60-333)	100 (30-233)
Prevention Trial	66	13.2	672 (206-1729)	554 (75-1346)
Treatment & Prevention	10	2.0	782 (250-1500)	741 (166-1557)
Sponsorship				
Industry Sponsor	112	22.4	195 (82-400)	187 (84-413)
Non-Industry Sponsor	388	77.6	177 (60-455)	100 (27-269)
Country Location				
USA Trial	179	35.8	200 (60-460)	95 (24-243)
Non-USA Trial	321	64.2	165 (60-426)	121 (39-324)
Number of Centers				· · · ·
Single Center	198	39.6	100 (37-290)	60 (20-213)
Multicenter	302	60.4	226 (100-500)	143 (53-401)

#### Table 1. Characteristics of Trial Cohort

a) Anticipated enrollment in the first registration record after trial start

b) At the 6-month mark, for the subset of trials which provide actual enrollment information

c) Includes Phase 1/2

d) Includes Phase 2/3

e) NA - Information not available in the ClinicalTrials.gov registration record

f) Trial Status at the 6-month mark since trial start




Figure 1. Flow Diagram for Trial Design Quality of Phase 2/3 and Phase 3 SARS-CoV-2 Trials

a) Refers to trial that is either placebo-controlled or has a standard of care comparator arm
b) Refers to a treatment trial with a clinical primary outcome or a prevention trial with either a clinical primary outcome or laboratory-confirmed SARS-CoV-2.

Table 2. Evaluation of	f Design Quality of	Trials Meant to	Inform Clinical Practice
	. Doolgii daaniy ol	That mount to	

Category	Number of Trials (N = 210)	Percent Total (%)
Randomized	200	95.2
Placebo-Controlled	179	85.2
Blinded <sup>a</sup>	100	47.6
Clinical Primary Outcome <sup>b</sup>	203	96.7
Includes at Risk Population <sup>c</sup>	208	99.0
Trials Meeting all 5 Criteria	92	43.8

a) Refers to trials that were at a minimum double-blinded

b) Treatment trials required a primary clinical outcome; prevention trials required either a primary clinical outcome or laboratory-confirmed SARS-CoV-2

c) Age of participants  $\geq$  60; the two trials not including participants  $\geq$  60 years of age included healthy adults without any additional factors putting them at greater risk for severe SARS-CoV-2 disease

Informative Condition	Trial Category	Proportion (95% exact CI)	P Value
Non-Redundant			
Sponsor	Industry	99.11 (95.13 – 99.98)	0.090
	Non-Industry	95.36 (92.77 – 97.23)	-
Country Location	USA Trial	96.09 (92.11 - 98.41)	1.000
	Non-USA Trial	96.26 (93.56 - 98.05)	
Trial Type	Treatment	96.23 (93.94 – 97.83)	0.731
	Prevention	95.45 (87.29 – 99.05)	
Number of Centers	Multicenter	95.03 (91.94 – 97.19)	0.100
	Single center	97.98 (94.91 – 99.45)	
Good Design			
Sponsor	Industry	73.91 (58.87 – 85.73)	3.898 x 10 <sup>-6</sup>
	Non-Industry	35.37 (28.07 – 43.20)	
Country Location	USA Trial	72.41 (59.10 – 83.34)	3.728 x 10 <sup>-7</sup>
	Non-USA Trial	32.89 (25.50 - 40.97)	
Trial Type	Treatment	39.18 (31.82 – 46.93)	0.013
	Prevention	62.86 (44.92 – 78.53)	
Number of Centers	Multicenter	48.68 (40.50 - 56.92)	0.029
	Single center	31.03 (19.54 – 44.54)	
Feasible			
Sponsor	Industry	71.43 (62.12 – 79.57)	0.096
	Non-Industry	79.12 (74.73 – 83.06)	
Country Location	USA Trial	69.83 (62.54 - 76.46)	0.004
	Non-USA Trial	81.62 (76.94 – 85.70)	
Trial Type	Treatment	78.30 (74.07 – 82.13)	0.022
	Prevention	71.21 (58.75 – 81.70)	
Number of Centers	Multicenter	73.18 (67.80 – 78.09)	0.006
	Single center	83.84 (77.96 - 88.68)	
Informative <sup>a</sup>			
Sponsor	Industry	52.17 (36.95 – 67.11)	3.587 x 10 <sup>-4</sup>
	Non-Industry	22.97 (16.46 – 30.60)	
Country Location	USA Trial	40.74 (27.57 – 54.97)	0.054
	Non-USA Trial	25.71 (18.71 – 33.78)	
Trial Type	Treatment	28.39 (21.44 – 36.18)	0.837
	Prevention	31.43 (16.85 – 49.29)	
Number of Centers	Multicenter	30.14 (22.83 – 38.27)	1.000
	Single center	29.17 (16.95 – 44.06)	

Table 3. Stratified Analysis of Redundancy, Design, Trial Feasibility and Informativeness by Sponsor, Country Location, Trial Type, Number of Trial Centers

a) Informative trials are those that meet all 3 informativeness criteria

# References

- 1. Glasziou PP, Sanders S, Hoffmann T. Waste in covid-19 research. *BMJ.* 2020;369:m1847. doi: 10.1136/bmj.m1847.
- 2. Kouzy R, Abi Jaoude J, Garcia Garcia CJ, El Alam MB, Taniguchi CM, Ludmir EB. Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic. *JAMA Netw Open.* 2020;3(7):e2015100. doi: 10.1001/jamanetworkopen.2020.15100.
- 3. London ÁJ, Kimmelman J. Against pandemic research exceptionalism. *Science*. 2020;368(6490):476-477. doi: 10.1126/science.abc1731.
- 4. Naci H, Kesselheim AS, Rottingen JA, Salanti G, Vandvik PO, Cipriani A. Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. *BMJ*. 2020;371:m3869. doi: 10.1136/bmj.m3869.
- 5. Jones CW, Woodford AL, Platts-Mills TF. Characteristics of COVID-19 clinical trials registered with ClinicalTrials.gov: cross-sectional analysis. *BMJ Open.* 2020;10(9):e041276. doi: 10.1136/bmjopen-2020-041276.
- Mehta HB, Ehrhardt S, Moore TJ, Segal JB, Alexander GC. Characteristics of registered clinical trials assessing treatments for COVID-19: a cross-sectional analysis. *BMJ Open.* 2020;10(6):e039978. doi: 10.1136/bmjopen-2020-039978.
- 7. Zarin DA, Goodman SN, Kimmelman J. Harms From Uninformative Clinical Trials. *JAMA*. 2019;322(9):813-814. doi: 10.1001/jama.2019.9892.
- Fragkou PC, Belhadi D, Peiffer-Smadja N, Moschopoulos CD, Lescure FX, Janocha H, et al. Review of trials currently testing treatment and prevention of COVID-19. *Clin Microbiol Infect.* 2020;26(8):988-998. doi: 10.1016/j.cmi.2020.05.019.
- 9. Pundi K, Perino AC, Harrington RA, Krumholz HM, Turakhia MP. Characteristics and Strength of Evidence of COVID-19 Studies Registered on ClinicalTrials.gov. *JAMA Intern Med.* 2020;180(10). doi: 10.1001/jamainternmed.2020.2904.
- 10. Janiaud P, Axfors C, Van't Hooft J, et al. The worldwide clinical trial research response to the COVID-19 pandemic the first 100 days. *F1000Res.* 2020;9:1193. doi.org/10.12688/f1000research.26707.2.
- 11. World Health Organization. WHO R&D Blueprint COVID 19 Experimental Treatments. 2020.
- World Health Organization. Clinical management of COVID-19 Interim Guidance. 27 May 2020. Available from: https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoVclinical-2020.5-eng.pdf. Accessed 2020-09-24.
- 13. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database--update and key issues. *N Engl J Med.* 2011;364(9):852-860. doi: 10.1056/NEJMsa1012065.
- 14. U.S. Food & Drug Association. COVID 19: Developing Drugs and Biological Products for Treatment or Prevention, Guidance for Industry. May 2020.

Available from: <u>https://www.fda.gov/media/137926/download</u> Accessed June 18 2020.

- 15. Carlisle B, Kimmelman J, Ramsay T, MacKinnon N. Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials. *Clin Trials.* 2015;12(1):77-83. doi: 10.1177/1740774514558307.
- 16. Carlisle BG. Numbat Systematic Review Manager. The Grey Literature. 2014. Available from: <u>https://numbat.bgcarlisle.com</u>.
- 17. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2013. Available from: http://R-project.org.
- 18. Hutchinson N, Carlisle B, Klas K, Polak M, Kimmelman J, Waligora M. The informativeness of trials in COVID-19: Lessons learned from the Coronavirus pandemic. Available from: <u>https://osf.io/fp726/</u>. doi: 10.17605/OSF.IO/FP726.
- 19. Carlisle B. C19InformAnalysis. Available from: https://codeberg.org/bgcarlisle/C19InformAnalysis.
- 20. Janiaud P, Axfors C, Ioannidis JPA, Hemkens LG. Recruitment and Results Reporting of COVID-19 Randomized Clinical Trials Registered in the First 100 Days of the Pandemic. *JAMA Netw Open.* 2021;4(3):e210330. doi: 10.1001/jamanetworkopen.2021.0330.
- 21. Norrie JD. Remdesivir for COVID-19: challenges of underpowered studies. *The Lancet.* 2020;395(10236):1525-1527. doi: 10.1016/S0140-6736(20)31023-0.
- 22. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The Lancet.* 2020;395(10236):1569-1578. doi: 10.1016/S0140-6736(20)31022-9.
- 23. Venkatraman N, Silman D, Folegatti PM, Hill AVS. Vaccines against Ebola virus. *Vaccine.* 2018;36(36):5454-5459. doi: 10.1016/j.vaccine.2017.07.054.
- 24. Cunniffe NG, Gunter SJ, Brown M, Burge SW, Coyle C, et al. How achievable are COVID-19 clinical trial recruitment targets? A UK observational cohort study and trials registry analysis. *BMJ Open.* 2020;10(10):e044566. doi: 10.1136/bmjopen-2020-044566.
- 25. von Cube M, Grodd M, Wolkewitz M, Hazard D, Wengenmayer T, Canet E, et al. Harmonizing Heterogeneous Endpoints in Coronavirus Disease 2019 Trials Without Loss of Information. *Crit Care Med.* 2021;49(1):e11-e19. doi: 10.1097/CCM.00000000004741.
- 26. Zarin DA, Rosenfeld S. Lack of harmonization of coronavirus disease ordinal scales. *Clin Trials.* 2021;18(2):263-264. doi: 10.1177/1740774520972082.
- 27. Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gülmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. *The Lancet.* 2014;383(9912):156-165. doi: 10.1016/S0140-6736(13)62229-1.
- 28. Chan A-W, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, et al. Increasing value and reducing waste: addressing inaccessible research. *The Lancet.* 2014;383(9913):257-266. doi: 10.1016/S0140-6736(13)62296-5.

- 29. Glasziou P, Altman DG, Bossuyt P, Boutron I, Clarke M, Julious S, et al. Reducing waste from incomplete or unusable reports of biomedical research. *The Lancet.* 2014;383(9913):267-276. doi: 10.1016/S0140-6736(13)62228-X.
- 30. Ioannidis JPA, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al. Increasing value and reducing waste in research design, conduct, and analysis. *The Lancet.* 2014;383(9912):166-175. doi: 10.1016/S0140-6736(13)62227-8.
- 31. Moher D, Glasziou P, Chalmers I, Nasser M, Bossuyt PMM, Korevaar DA, et al. Increasing value and reducing waste in biomedical research: who's listening? *The Lancet.* 2016;387(10027):1573-1586. doi: 10.1016/S0140-6736(15)00307-4.
- 32. Salman RA-S, Beller E, Kagan J, Hemminki E, Phillips RS, Savulescu J, et al. Increasing value and reducing waste in biomedical research regulation and management. *The Lancet.* 2014;383(9912):176-185. doi: 10.1016/S0140-6736(13)62297-7.
- 33. Yordanov Y, Dechartres A, Atal I, Tran VT, Boutron I, Crequit P, et al. Avoidable waste of research related to outcome planning and reporting in clinical trials. *BMC Med.* 2018;16(1):87. doi: 10.1186/s12916-018-1083-x.
- 34. Gelinas L, Lynch HF, Bierer BE, Cohen IG. When clinical trials compete: prioritising study recruitment. *J Med Ethics.* 2017;43(12):803-809. doi: 10.1136/medethics-2016-103680.
- 35. North CM, Dougan ML, Sacks CA. Improving Clinical Trial Enrollment In the Covid-19 Era and Beyond. *N Engl J Med.* 2020;383(15):1406-1408. doi: 10.1056/NEJMp2019989.
- 36. Meyer MN, Gelinas L, Bierer BE, Hull SC, Joffe S, Magnus D, et al. An ethics framework for consolidating and prioritizing COVID-19 clinical trials. *Clin Trials*. 2021;18(2):226-233. doi:10.1177/1740774520988669.
- 37. Angus DC, Gordon AC, Bauchner H. Emerging Lessons from COVID-19 for the US Clinical Research Enterprise. *JAMA*. 2021;325(12):1159-1161. doi:10.1001/jama.2021.3284.